Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea
09. Mai 2024 08:00 ET
|
Apnimed, Inc.
Apnimed Completes Enrollment in Ph3 LunAIRo Study of AD109, Potential 1st Nighttime Oral Tx for Obstructive Sleep Apnea; Presents Study Design at ATS2024